Drug shortage
Atazanavir Sulfate Oral Powder · Bristol Myers Squibb Co.
FDA drug shortage · To Be Discontinued · updated Jun 4, 2025
Key facts
| Generic name | Atazanavir Sulfate Oral Powder |
|---|---|
| Company | Bristol Myers Squibb Co. |
| Presentation | Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10) |
| Dosage form | Oral Powder |
| Status | To Be Discontinued |
| Therapeutic category | Antiviral |
| Package NDCs | 0003-3638-10 |
| First posted | Jun 4, 2025 |
| Last updated | Jun 4, 2025 |
| Discontinued | Jun 4, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: